Extent of exposure to study medication—safety set
| Daily dose (mg) | Cannabis extract (N=143) | Placebo (N=134) | ||
| End of titration period | End of study period | End of titration period | End of study period | |
| n (%) | n (%) | n (%) | n (%) | |
| 2.5 | 2 (1.4) | 4 (2.8) | 0 (0.0) | 0 (0.0) |
| 5.0 | 5 (3.5) | 6 (4.2) | 0 (0.0) | 0 (0.0) |
| 7.5 | 2 (1.4) | 5 (3.5) | 0 (0.0) | 0 (0.0) |
| 10.0 | 15 (10.5) | 13 (9.1) | 2 (1.5) | 3 (2.2) |
| 12.5 | 4 (2.8) | 7 (4.9) | 2 (1.5) | 2 (1.5) |
| 15.0 | 16 (11.2) | 13 (9.1) | 6 (4.5) | 7 (5.2) |
| 17.5 | 4 (2.8) | 3 (2.1) | 0 (0.0) | 0 (0.0) |
| 20.0 | 6 (4.2) | 8 (5.6) | 3 (2.2) | 8 (6.0) |
| 22.5 | 4 (2.8) | 4 (2.8) | 0 (0.0) | 1 (0.7) |
| 25.0 | 67 (46.9) | 35 (24.5) | 117 (87.3) | 93 (69.4) |
| Not applicable* | 16 (11.2) | 43 (30.1) | 4 (3.0) | 20 (14.9) |
| Missing | 2 (1.4) | 2 (1.4) | 0 (0.0) | 0 (0.0) |
↵* Not applicable because patients discontinued taking study medication.
%, percentage (based on N); n, number of patients with data available; N, number of patients in specified treatment group.